Drug · Small Molecule
Megestrol
CI-DRUG-00000669Explore in graph →CHEMBL1201139 Approved
Regulatory
Approvals (14)
Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.
- Source
- Health Canada — Drug Product Database (DPD)
- Dataset
- Health Canada DPD
- Version
- dpd-2026-09-11
- Retrieved
- Sep 11, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- regulatory
- License
- Open Government Licence – Canada (https://open.canada.ca/en/open-government-licence-canada)
- Run
- ING-HEALTHCANADADPD-20260911-000001
| Jurisdiction · authority | Cancer | Indication | Status | Approval date | Source |
|---|---|---|---|---|---|
| CA Health Canada | — | Marketed in Canada as MEGESTROL-160 - TAB 160 MG (DIN 02223112) under ATC L02AB01 MEGESTROL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | withdrawnsource: Cancelled Post Marketsince Jul 13, 2010 | Feb 27, 1997 | health-canada-dpd |
| CA Health Canada | — | Marketed in Canada as MEGESTROL-40 - TAB 40MG (DIN 02223104) under ATC L02AB01 MEGESTROL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | withdrawnsource: Cancelled Post Marketsince Jul 13, 2010 | Feb 27, 1997 | health-canada-dpd |
| CA Health Canada | — | Marketed in Canada as MEGESTROL (DIN 02185415) under ATC L02AB01 MEGESTROL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | approved | Dec 31, 1996 |
Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.
Data updated 15 days agoSource updated unknown
Derived
Development pipeline
Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.
| Scope | Stage | Max phase | Active | Recruiting | Phase 3 | Trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| All cancers | Approved | Phase 4 | 11 | 6 | 15 | 43 | 14 | CA, US | Aug 8, 1988 | 1987-12 |
| Malignant Breast Neoplasm | Approved | Phase 3 | 0 | 0 | 2 | 6 | 1 | US | Aug 8, 1988 | 1987-12 |
| Malignant Uterine Corpus Neoplasm | Phase3 | Phase 3 | 7 | 4 | 4 | 17 | 0 | — | — | 1987-12 |
| Malignant Liver Neoplasm | Phase3 | Phase 3 | 0 | 0 | 1 | 1 | 0 |
Curated evidence
Clinical evidence (0)
CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.
Data not yet available
Clinical trials
Trials with this intervention (43)
Most recently updated first, 50 per page.
- Source
- ClinicalTrials.gov
- Dataset
- ClinicalTrials.gov API v2 studies
- Retrieved
- Sep 18, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00420563 | Metronomic Chemotherapy by Cyclophosphamide Versus Megestrol in Palliative Cancer(PALANGI) | completed | Phase 2 | 88 | Centre Oscar LambretOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT04939090 | Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients | active not recruiting |